Two dimensional difference gel electrophoresis analysis of cerebrospinal fluid in tuberculous meningitis patients

Journal of Proteomics

Volumn 74, Issue 10, 2011, Pages 2194-2203

  Kataria, Jitender ^a   Rukmangadachar, Lokesh A ^a   Hariprasad, Gururao ^a   O, Jithesh ^a   Tripathi, Manjari ^a   Srinivasan, Alagiri ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

2D DIGE; Cerebrospinal fluid; Diagnostic marker; Mass spectrometry; Tuberculous meningitis

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; BACTERIAL PROTEIN; BIOLOGICAL MARKER; GLIAL FIBRILLARY ACIDIC PROTEIN;

ADULT; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; FUNGAL MENINGITIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MASS SPECTROMETRY; MYCOBACTERIUM; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; TUBERCULOUS MENINGITIS; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; VALIDATION PROCESS; WESTERN BLOTTING;

ADULT; ARACHIDONATE 5-LIPOXYGENASE; BIOLOGICAL MARKERS; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; MALE; MASS SPECTROMETRY; MENINGITIS, CRYPTOCOCCAL; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MENINGEAL; TWO-DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS;

EID: 80051980827     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2011.06.020     Document Type: Article

References (65)

1. Hopewell P.C. Overview of clinical tuberculosis. Tuberculosis pathogenesis, protection, and control 1994, 25-46. American Society for Microbiology, Washington DC. B.R. Bloom (Ed.).
2. Harrison's Principle of Internal Medicine 2007, 2621-2646. 17th edition.
3. Rieder H.L., Snider D.E., Cauthen G.M. Extra pulmonary tuberculosis in the United States. Am Rev Respir Dis 1990, 141:347-351.
4. Garcia-Monco J.C. Central nervous system tuberculosis. Neurol Clin 1999, 17:737-759.
5. World Health Organization(WHO) Global Tb control Report 2009.
6. Jarvis J.N., Meintjes G., Williams A., Brown Y., Crede T., Harrison T.S. Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases. BMC Infect Dis Mar 2010, 15:10-67.
7. Rock B.R., Olin M., Baker C.A., Molitor T.W., Peterson P.K. Central nervous system tuberculosis: pathogenesis and clinical aspects. Clin Microbiol Rev April 2008, 21(2):243-261.
8. Garg P.K. Tuberculosis of the central nervous system. Post Grad Med J 1999, 75:133-140.
9. Sutlas P.N., Unal A., Forta H., Senol S., Kirbas D. Tuberculous meningitis in adults: review of 61 cases. Infection 2003, 31:387-391.
10. Bhigjee A.I., Padayachee R., Paruk H., Hallwirth-Pillay K.D., Marais S., Connoly C. Diagnosis of tuberculous meningitis: clinical and laboratory parameters. Int J Infect Dis Jul 2007, 11(4):348-354.
11. Jesse S., Steinacker P., Lehnert S., Sdzuj M., Cepek L., Tumani H., et al. A proteomic approach for the diagnosis of bacterial meningitis. PLoS One Apr 8 2010, 5(4).
12. Liu S., Bai S., Qin Z., Yang Y., Cui Y., Qin Y. Quantitative proteomic analysis of the cerebrospinal fluid of patients with multiple sclerosis. J Cell Mol Med Aug 2009, 13(8A):1586-1603.
13. Brechlin P., Jahn O., Steinacker P., Cepek L., Kratzin H., Lehnert S., et al. Cerebrospinal fluid-optimized two-dimensional difference gel electrophoresis (2-D DIGE) facilitates the differential diagnosis of Creutzfeldt-Jakob disease. Proteomics Oct 2008, 8(20):4357-4366.
14. Ahuja G.K., Mohan K.K., Prasad K., Behari M. Diagnostic criteria for tuberculous meningitis and their validation. Tuber Lung Dis Apr 1994, 75(2):149-152.
15. Satishchandra P., Mathew T., Gadre G., Nagarathna S., Chandramukhi A., Mahadevan A., et al. Cryptococcal meningitis: clinical, diagnostic and therapeutic overviews. Neurol India 2007, 55(3):226-232.
16. Hye A., Lynham S., Thambisetty M., Causevic M., Campbell J., Byers H.L., et al. Proteome-based plasma biomarkers for Alzheimer's disease. Brain Nov 2006, 129(Pt 11):3042-3050.
17. Shores K.S., Knapp D.R. Assessment approach for evaluating high abundance protein depletion methods for cerebrospinal fluid (CSF) proteomic analysis. J Proteome Res Sep 2007, 6(9):3739-3751. Epub 2007 Aug 16.
18. Gao W.M., Chadha M.S., Berger R.P., Omenn G.S., Allen D.L., Pisano M., et al. A gel-based proteomic comparison of human cerebrospinal fluid between inflicted and non-inflicted pediatric traumatic brain injury. J Neurotrauma Jan 2007, 24(1):43-53.
19. Rozek W., Ricardo-Dukelow M., Holloway S., Gendelman H.E., Wojna V., Melendez L.M., et al. Cerebrospinal fluid proteomic profiling of HIV-1-infected patients with cognitive impairment. J Proteome Res Nov 2007, 6(11):4189-4199. Epub 2007 Oct 12.
20. Donald P.R., Schoeman J.F. Tuberculous meningitis. N Engl J Med Oct 21 2004, 35(17):1719-1720.
21. Giunta S., Galeazzi R., Marcellini M., Corder E.H., Galeazzi L. The inflammation-sensitive protein alpha 1-anti-chymotrypsin neutralizes fibrillar aggregation and cytotoxicity of the beta-amyloid peptide more effectively than alpha 1-antitrypsin. Clin Biochem Aug 2007, 40(12):887-892. Epub 2007 Apr 20.
22. Adam P., Sobek O., Táborskỳ L., Hildebrand T., Průcha M., Hyánek J., et al. Complete proteinogram of cerebrospinal fluid and its contribution to the diagnostics of inflammatory and autoimmune diseases of the central nervous system. Sb Lek 2003, 104(1):1-12.
23. Mamełka B., Lobos M., Sass-Just M., Dworniak D., Urbaniak A., Terlecka M., et al. Does the assay of acute phase protein concentrations in cerebrospinal fluid and/or in serum in patient with viral meningitis have a diagnostic value? Part II. Lymphocytic meningitis caused by echo 30 virus. Przegl Epidemiol 2004, 58(2):351-359.
24. Serhan C.N. Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL): a jungle of cell-cell interactions or a therapeutic opportunity?. Prostaglandins Feb 1997, 53(2):107-137.
25. Werz O., Tretiakova I., Michel A., Ulke-Lemee A., Hörnig M., Franke L., et al. Caspase-mediated degradation of human 5-lipoxygenase in B lymphocytic cells. Proc Natl Acad Sci U S A Sep 13 2005, 102(37):13164-13169. Epub 2005 Aug 31.
26. Bafica A., Scanga C.A., Serhan C., Machado F., White S., Sher A., et al. Host control of Mycobacterium tuberculosis is regulated by 5-lipoxygenase-dependent lipoxin production. J Clin Invest Jun 2005, 115(6):1601-1606.
27. Chen M., Divangahi M., Gan H., Shin D.S., Hong S., Lee D.M., et al. Lipid mediators in innate immunity against tuberculosis: opposing roles of PGE2 and LXA4 in the induction of macrophage death. J Exp Med Nov 24 2008, 205(12):2791-2801.
28. Divangahi M., Desjardins D., Nunes-Alves C., Remold H.G., Behar S.M. Eicosanoid pathways regulate adaptive immunity to Mycobacterium tuberculosis. Nat Immunol Aug 2010, 11(8):751-758. Epub 2010 Jul 11.
29. Herb F., Thye T., Niemann S., Browne E.N., Chinbuah M.A., Gyapong J., et al. ALOX5 variants associated with susceptibility to human pulmonary tuberculosis. Hum Mol Genet Apr 1 2008, 17(7):1052-1060.
30. Drazen J.M., Yandava C.N., Dubé L., Szczerback N., Hippensteel R., Pillari A., et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet Jun 1999, 22(2):168-170.
31. Drazen J.M., Israel E. Treatment of chronic stable asthma with drugs active on the 5-lipoxygenase pathway. Int Arch Allergy Immunol 1995, 107(1-3):319-320.
32. Kalayci O., Birben E., Sackesen C., Keskin O., Tahan F., Wechsler M.E., et al. ALOX5 promoter genotype, asthma severity and LTC production by eosinophils. Allergy 2006, 61(1):97-103.
33. De Caterina R., Zampolli A. From asthma to atherosclerosis-5-lipoxygenase, leukotrienes, and inflammation. N Engl J Med 2004, 350(1):4-7.
34. Dwyer J.H., Allayee H., Dwyer K.M., Fan J., Wu H., Mar R., et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med 2004, 350(1):29-37.
35. Serhan C.N., Drazen J.M. Antiinflammatory potential of lipoxygenase-derived eicosanoids: a molecular switch at 5 and 15 positions?. J Clin Invest 1997, 99(6):1147-1148.
36. Trysberg E., Nylen K., Rosengren L.E., Tarkowski A. Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement. Arthritis Rheum 2003, 48(10):2881-2887.
37. Sporer B., Missler U., Magerkurth O., Koedel U., Wiesmann M., Pfister H.W. Evaluation of CSF Glial Fibrillary Acidic Protein (GFAP) as a putative marker for HIV-associated dementia. Infection 2004, 32:20-23.
38. Lejon V., Rosengren L.E., Buscher P., Karlsson J.E., Sema H.N. Detection of light subunit neurofilament and glial fibrillary acidic protein in cerebrospinal fluid of Trypanosoma brucei gambiense-infected patients. Am J Trop Med Hyg 1999, 60(1):94-98.
39. Linker R.A., Brechlin P., Jesse S., Steinacker P., Lee D.H., Asif A.R., et al. Proteome profiling in murine models of multiple sclerosis: identification of stage specific markers and culprits for tissue damage. PLoS One 2009, 4(10).
40. Kadurugamuwa J.L., Modi K., Coquoz O., Rice B., Smith S., Contag P.R., et al. Reduction of astrogliosis by early treatment of pneumococcal meningitis measured by simultaneous imaging, in vivo, of the pathogen and host response. Infect Immun 2005, 73(12):7836-7843.
41. Nau R., Wellmer A., Soto A., Koch K., Schneider O., Schmidt H., et al. Rifampin reduces early mortality in experimental Streptococcus pneumoniae meningitis. J Infect Des 1999, 179:1557-1560.
42. Kaminskaia G.O., Martynova E.V., Serebrianaia B.A., Komissarova O.G. Blood anticoagulation system in the hypercoagulation syndrome in patients with pulmonary tuberculosis. Probl Tuberk Bolezn Legk 2008, 11:35-39.
43. Lee M.H., Nahm C.H., Choi J.W. Thrombin-antithrombin III complex, proinflammatory cytokines, and fibrinolytic indices for assessing the severity of inflammation in pleural effusions. Ann Clin Lab Sci 2010, 40(4):342-347.
44. Ignatius M.J., Gebicke-Härter P.J., Skene J.H., Schilling J.W., Weisgraber K.H., Mahley R.W., et al. Expression of apolipoprotein E during nerve degeneration and regeneration. Proc Natl Acad Sci U S A 1986, 83(4):1125-1129.
45. Pitas R.E., Boyles J.K., Lee S.H., Foss D., Mahley R.W. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim Biophys Acta 1987, 917(1):148-161.
46. Guo L., LaDu M.J., Van Eldik L.J. A dual role for apolipoprotein e in neuroinflammation: anti- and pro-inflammatory activity. J Mol Neurosci 2004, 23(3):205-212.
47. Wang L., Chen W.Z., Wu M.P. Apolipoprotein A-I inhibits chemotaxis, adhesion, activation of THP-1 cells and improves the plasma HDL inflammatory index. Cytokine 2010, 49(2):194-200.
48. Singh P.P., Singh M., Mastana S.S. APOE distribution in world populations with new data from India and the UK. Ann Hum Biol 2006, 33(3):279-308.
49. Taghi N.F., Batool S.M., Mansur S., Alireza M. Apolipoprotein E polymorphism in tuberculosis patients. J Appl Sci 2008, 8(4):719-722.
50. Kay A., Petzold A., Kerr M., Keir G., Thompson E., Nicoll J. Decreased cerebrospinal fluid apolipoprotein E after subarachnoid hemorrhage: correlation with injury severity and clinical outcome. Stroke 2003, 34(3):637-642.
51. Lynch J.R., Wang H., Mace B., Leinenweber S., Warner D.S., Bennett E.R., et al. A novel therapeutic derived from apolipoprotein E reduces brain inflammation and improves outcome after closed head injury. Exp Neurol 2005, 192(1):109-116.
52. Li F.Q., Sempowski G.D., McKenna S.E., Laskowitz D.T., Colton C.A., Vitek M.P. Apolipoprotein E-derived peptides ameliorate clinical disability and inflammatory infiltrates into the spinal cord in a murine model of multiple sclerosis. J Pharmacol Exp Ther 2006, 318(3):956-965.
53. Meyers C.D., Kashyap M.L. Pharmacologic augmentation of high-density lipoproteins: mechanisms of currently available and emerging therapies. Curr Opin Cardiol 2005, 20(4):307-312.
54. Chiesa G., Parolini C., Sirtori C.R. Acute effects of high-density lipoproteins: biochemical basis and clinical findings. Curr Opin Cardiol 2008, 23(4):379-385.
55. D'Aguanno S., Franciotta D., Lupisella S., Barassi A., Pieragostino D., Lugaresi A., et al. Protein profiling of Guillain-Barrè syndrome cerebrospinal fluid by two-dimensional electrophoresis and mass spectrometry. Neurosci Lett 2010, 485(1):49-54. Epub 2010 Aug 27.
56. Ryberg H., An J., Darko S., Lustgarten J.L., Jaffa M., Gopalakrishnan V., et al. Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics. Muscle Nerve 2010, 42(1):104-111.
57. Tumani H., Pfeifle M., Lehmensiek V., Rau D., Mogel H., Ludolph A.C., et al. Candidate biomarkers of chronic inflammatory demyelinating polyneuropathy (CIDP): proteome analysis of cerebrospinal fluid. J Neuroimmunol 2009, 214(1-2):109-112. Epub 2009 Jul 9.
58. Santos S.D., Lambertsen K.L., Clausen B.H., Akinc A., Alvarez R., Finsen B., et al. CSF transthyretin neuroprotection in a mouse model of brain ischemia. J Neurochem 2010, 115(6):1434-1444.
59. Zhang Y.M., Rock C.O. Membrane lipid homeostasis in bacteria. Nat Rev Microbiol 2008, 6(3):222-233.
60. Matsumoto K., Kusaka J., Nishibori A., Hara H. Lipid domains in bacterial membranes. Mol Microbiol 2006, 61(5):1110-1117.
61. Ernst C.M., Staubitz P., Mishra N.N., Yang S.J., Hornig G., Kalbacher H., et al. The bacterial defensin resistance protein MprF consists of separable domains for lipid lysinylation and antimicrobial peptide repulsion. PLoS Pathog 2009, 5(11):e1000660. Epub 2009 Nov 13.
62. Pinto R., Tang Q.X., Britton W.J., Leyh T.S., Triccas J.A. The Mycobacterium tuberculosis cysD and cysNC genes form a stress-induced operon that encodes a tri-functional sulfate-activating complex. Microbiology 2004, 150(6):1681-1686.
63. Kazarian K., Cassani C., Rizzi M. Expression, purification and characterization of UvrD2 helicase from Mycobacterium tuberculosis. Protein Expr Purif 2010, 69(2):215-218. Epub 2009 Sep 18.
64. Anishetty S., Pulimi M., Pennathur G. Potential drug targets in Mycobacterium tuberculosis through metabolic pathway analysis. Comput Biol Chem 2005, 29(5):368-378. Epub 2005 Oct 6.
65. Zheng H., Lu L., Wang B., Pu S., Zhang X., Zhu G., et al. Genetic basis of virulence attenuation revealed by comparative genomic analysis of Mycobacterium tuberculosis strain H37Ra versus H37Rv. PLoS One 2008, 3(6):e2375.